Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed...
22 KB (1,836 words) - 05:53, 21 September 2024
Daratumumab/hyaluronidase, sold under the brand name Darzalex Faspro, is a fixed-dose combination medication for the treatment of adults with newly diagnosed...
11 KB (954 words) - 06:56, 8 August 2024
cyclophosphamide, bortezomib and dexamethasone (CyBorD) with daratumumab added. Daratumumab, a monoclonal antibody to CD38, a protein that is expressed...
16 KB (1,638 words) - 20:43, 24 September 2024
vitro during trastuzumab treatment. Multiple myeloma can be treated with daratumumab (Darzalex) monoclonal antibody. Studies with in vitro materials and patient...
13 KB (1,661 words) - 22:18, 9 December 2023
cancer (Seagen) Marketed by partners: Darzalex (IV) (daratumumab) / Darzalex Faspro (SC) (daratumumab and hyaluronidase) for the treatment of all stages...
26 KB (1,906 words) - 04:10, 19 June 2024
marker in leukemia. Daratumumab (Darzalex) which targets CD38 has been used in treating multiple myeloma. The use of Daratumumab can interfere with pre-blood...
35 KB (3,825 words) - 07:13, 15 October 2024
groupings include one or more of a monoclonal antibody (e.g., isatuximab or daratumumab), an immunomodulatory agent (e.g., lenalidomide or pomalidomide), and...
131 KB (13,506 words) - 01:17, 6 November 2024
(Rituxan Hycela), trastuzumab/hyaluronidase-oysk (Herceptin Hylecta), daratumumab/hyaluronidase-fihj (Darzalex Faspro), and pertuzumab/trastuzumab/hyaluronidase–zzxf...
34 KB (3,092 words) - 05:38, 14 September 2024
1007/978-3-540-47648-1_1505. ISBN 978-3-540-36847-2. "Summary of opinion: Darzalex,daratumumab". Case Medical Research. 2019-12-13. doi:10.31525/cmr-242ed13. ISSN 2643-4652...
25 KB (1,860 words) - 04:49, 26 July 2024
symptoms of the TEMPI syndrome was reported with the drugs bortezomib, daratumumab and autologous stem cell transplantation. In 2010, the case of a man...
5 KB (363 words) - 01:31, 29 October 2024
daratumumab is in the recognition of the different amino acid groups. Isatuximab identifies 23 amino acids of CD38 to the contrary with daratumumab who...
31 KB (3,243 words) - 09:39, 22 October 2024
Retrieved 23 January 2020. "Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". DailyMed...
137 KB (4,083 words) - 21:25, 19 October 2024
Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma" at ClinicalTrials.gov Clinical trial...
46 KB (4,813 words) - 05:06, 15 October 2024
McCudden, C. (2016). "Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference". Clin Chem Lab Med. 54...
17 KB (2,229 words) - 20:08, 6 February 2024
Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple...
11 KB (746 words) - 15:52, 3 June 2024
Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin...
12 KB (821 words) - 02:57, 12 October 2024
are being tested in multiple myeloma and non-Hodgkin's lymphoma e.g. Daratumumab or Celgene's MOR202. CD39 Also known as Ectonucleoside triphosphate diphosphohydrolase...
96 KB (467 words) - 19:33, 6 August 2024
normal cell lines. There are newer medications (ixazomib, carfilzomib, daratumumab, elotuzumab) under research for the treatment of multiple myeloma that...
30 KB (3,354 words) - 02:30, 21 June 2024
dosages, safety, and efficacy of adding daratumumab to the EPOCH regimen in treating patients with PBL. Daratumumab is a prepared monoclonal antibody that...
25 KB (3,060 words) - 21:02, 23 January 2024
soft-tissue sarcoma Nivolumab Bristol-Myers Squibb head and neck cancer Daratumumab Janssen multiple myeloma Rucaparib Clovis Oncology BRCA-mutated ovarian...
34 KB (180 words) - 17:05, 14 October 2024
L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab pasudotox L01FC01 Daratumumab L01FC02 Isatuximab L01FD01 Trastuzumab L01FD02 Pertuzumab L01FD03 Trastuzumab...
12 KB (877 words) - 15:36, 25 January 2024
(INN) dapsone (INN) daptomycin (INN) Daranide darapladib (USAN, INN) daratumumab (INN) Daraprim darbepoetin alfa (INN) Darbid. Redirects to Isopropamide...
6 KB (331 words) - 04:31, 10 November 2024
carfilzomib, lenalidomide, pomalidomide, and a monoclonal antibody (daratumumab or isatuximab); nearly all had also undergone hematopoietic stem cell...
30 KB (2,715 words) - 06:09, 16 July 2024
5/27/2016 subcutaneous humanized IL2R Multiple sclerosis 761029 Link daratumumab Darzalex Janssen Biotech 11/16/2015 intravenous fully human CD38 Multiple...
59 KB (4,170 words) - 07:03, 20 October 2024
with a cytotoxic antibody directed at CD38, Daratumumab. A phase 2 clinical study on the effects of Daratumumab on ENTCL-NT sponsored by Janssen Research...
46 KB (5,496 words) - 23:40, 12 October 2024
The monoclonal antibody against the plasma cell surface protein CD38 daratumumab may also be used with very high efficacy against AL amyloidosis. B-cell...
14 KB (1,590 words) - 21:26, 19 February 2024
Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin...
12 KB (758 words) - 23:46, 14 March 2024
myeloma] seem promising, such as monoclonal antibodies (anti-CD38 — daratumumab or anti-CS1 — elotuzumab) or the kinesin protein inhibitor Arry-520."...
11 KB (1,110 words) - 22:35, 26 August 2023
(+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin Enoticumab§...
5 KB (368 words) - 15:29, 21 August 2024
(+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin Enoticumab§...
3 KB (129 words) - 01:04, 19 July 2023